Clinical Evidence

Delve into clinical research studies and more

Clinical research lies at the heart of who we are. Vantive uses scientific evidence systematically, and transparently, to inform the development of new state-of-the-art solutions for patients around the world. Here you can find various studies, white papers and articles concerning important topics across the wide range of therapy areas served by Vantive.

HDx therapy enabled by the Theranova Dialyzer
An initial evaluation of expanded hemodialysis on hospitalizations, drug utilization, costs, and patient utility in Colombia.
Visit resource site
HDx therapy enabled by the Theranova Dialyzer
Are medium cut-off membranes the future, or the promising reality for chronic hemodialysis patients?.
Visit resource site
HDx therapy enabled by the Theranova Dialyzer
Arteriovenous fistula as the vascular access contributes to better survival of hemodialysis patients with COVID-19 infection
Visit resource site
HDx therapy enabled by the Theranova Dialyzer
Assessment of safety and efficacy of expanded hemodialysis using medium cutoff dialyzer in comparison to hemodiafiltration.
Visit resource site
PD
Assessment of the association between increasing membrane pore size and endotoxin permeability using a novel experimental dialysis simulation set-up
Visit resource site
PD
Bicarbonate/lactate-based peritoneal dialysis solution increases cancer antigen 125 and decreases hyaluronic acid levels - Jones S, et al.
Visit resource site
HD
Biofeedback dialysis for hypotension and hypervolemia: a systematic review and meta-analysis - Nesrallah et al.
Visit resource site
HDx therapy enabled by the Theranova Dialyzer
Bisphenol A and Bisphenol S in Hemodialyzers
Visit resource site
HDx therapy enabled by the Theranova Dialyzer
Budget-Impact Analysis of Adopting Expanded Hemodialysis (HDX) Via Theranova® in Korea
Visit resource site
HD
C-reactive Protein: Repeated Measurements will Improve Dialysis Patient Care - Cobo et al.
Visit resource site
HDx therapy enabled by the Theranova Dialyzer
Can better efficacy of middle weight molecules removal in dialysis patients treated with medium cut-off membranes predict superiority over conventional high flux dialysers?
Visit resource site
HDx therapy enabled by the Theranova Dialyzer
Cardiovascular disease in dialysis patients
Visit resource site

Important Safety Information

INTENDED USE

The Theranova Dialyzer is indicated for patients with chronic kidney failure who are prescribed intermittent hemodialysis. It provides an expanded solute removal profile with increased removal of various middle molecules (up to 45 kDa) that may play a pathologic role in the uremic clinical syndrome. The Theranova Dialyzer is not intended for hemofiltration or hemodiafiltration therapy. The total extracorporeal blood volume for the Theranova Dialyzer and the set should represent less than 10% of the patient's blood volume.

For single use only.

 

Rx Only. For safe and proper use of the products mentioned herein, please refer to the appropriate Operator’s Manual or Instructions for Use.

 

Vantive, HDx and Theranova are trademarks of Vantive Health LLC or its affiliates.